J&J underwhelms with modest EPS forecast
However you slice it, J&J's prospect of earnings growth looks bleak as economic and competitive 'headwinds' continue.
The company said it expects earnings per share of $5.05 to $5.15 excluding costs of a major acquisition.
That estimate badly missed Wall Street expectations ($5.20) and would represent a measly gain on the adjusted EPS the company just reported ($5). The news sent the company’s stock down before markets opened today. The shares recovered, trading up less than 1% to $65.16 midday.
The company cited a stronger dollar, higher costs and pricing pressure as reason for the temperate forecast. Those challenges are on top of generic competition, a lagging US economy and two years of recalls, government investigations and sanctions on the company’s over-the-counter drug business.
J&J’s CEO William Weldon calls them "headwinds."
This is the pharmaceutical industry in 2012. Lilly blamed its weak outlook on rapid erosion of anti-psychotic drug Zyprexa, which began facing generic competition late last year.
J&J has some unique problems, including legal costs related to illegal marketing of its own anti-psychotic drug Risperdal and expenses related to product liability and the recall fiasco. (Those and other costs contributed to an almost 90% plunge in fourth-quarter income.)
And, to be sure, the company isn’t a pure pharmaceutical maker. It’s much more diverse with a sizable medical device business that’s about to get a whole lot bigger with the planned $20 billion takeover of Synthes. But J&J faces pressures seen in other big drug companies, most notably the patent expirations. J&J sales last year were hurt by generic competition for Levaquin, a treatment for bacterial infections, for instance. The US economy is hurting J&J’s orthopedics business as some patients put off elective surgeries.
While the various costs contributed to lower net income in 2011, sales rose 5.6% to $65 billion. US sales, however, declined almost 2%, the company said. (Sales in this country dropped more than 3% in the fourth quarter.)
"This weaker-than-expected operational quarter could confirm investor fears of a protracted and broad economic slowdown," says Leerink Swann analyst Rick Wise. He rates the stock a buy with a $70 price target.
In the past six months, J&J’s stock has declined almost 3%, which lags the share performance of rivals Pfizer (PFE), Merck (MRK), Bristol-Myers Squibb (BMY) and Lilly, which have all recorded gains in that period.
More from Minyanville:
- Tablets, E-Readers Double Market Penetration, Says Report
- Commodity-Related Currencies Suggest Some Bullish Action
- Central Banks' Cash Helping Investors Look the Other Way
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Excitement is growing about the company's new iPhone, expected this fall.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.